Is Aztreonam Lysine for Inhalation Effective in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection?
|
|
- Rosaline Simmons
- 7 years ago
- Views:
Transcription
1 Philadelphia College of Osteopathic Medicine PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Aztreonam Lysine for Inhalation Effective in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection? Christine Shevchenko Philadelphia College of Osteopathic Medicine, Follow this and additional works at: Part of the Medicine and Health Sciences Commons Recommended Citation Shevchenko, Christine, "Is Aztreonam Lysine for Inhalation Effective in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection?" (2014). PCOM Physician Assistant Studies Student Scholarship. Paper 192. This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized administrator of For more information, please contact
2 Is Aztreonam Lysine for Inhalation Effective in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection? Christine Shevchenko, PA-S A SELECTIVE EVIDENCE BASED MEDICINE REVIEW In Partial Fulfillment of the Requirements For The Degree of Master of Science In Health Sciences Physician Assistant Department of Physician Assistant Studies Philadelphia College of Osteopathic Medicine Philadelphia, Pennsylvania December 20, 2013
3 ABSTRACT OBJECTIVE: The objective of this selective EBM review is to determine whether or not aztreonam lysine for inhalation is effective in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa airway infection. STUDY DESIGN: Review of three English language primary randomized controlled trials published in 2008, 2009, and DATA SOURCES: Three randomized, double-blind, placebo-controlled studies using Cochrane and Pubmed databases. OUCOMES MEASURED: Patient oriented outcomes measured included change in respiratory symptoms measured by the Cystic Fibrosis Questionnaire-Revised and need for additional antipseudomonal antibiotics indicative of pulmonary exacerbation. RESULTS: In both cystic fibrosis (CF) patients who have been treated with standard long term therapy and those who have not, 28 day therapy with aztreonam lysine for inhalation (AZLI) was shown to be effective in the treatment of chronic Pseudomonas aeruginosa airway infection. AZLI treatment showed statistical significance in the improvement of patient reported respiratory symptoms compared to placebo. Twice per day versus three times per day dosing did not show a significant impact on outcome. In CF patients with mild respiratory dysfunction, determined by a FEV 1 of > 75%, AZLI treatment did not significantly prevent need for additional antipseudomonal antibiotics during the course of the study. CONCLUSION: These studies determined that AZLI is more effective at reducing respiratory symptoms in CF patients with chronic P. aeruginosa airway infection than placebo. AZLI therapy does not significantly decrease the number of severe pulmonary exacerbations that would require further antipseudomonal antibiotics. Twice or three times per day dosing does not significantly affect the outcomes. KEY WORDS: aztreonam, monobactam, cystic fibrosis, Pseudomonas aeruginosa
4 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 1 INTRODUCTION Cystic fibrosis (CF) is a chronic, autosomal recessive disease of the secretory glands. 1,2 It is characterized by increased pulmonary secretions which are especially thick and difficult to clear. 1 Common complications include superimposed airway infections and pancreatic insufficiency due to mucus blocked ducts. 1 The most common pathogen of airway infections in CF patients, and one of the most difficult to eradicate, is Pseudomonas aeruginosa (P. aeruginosa). 1 Chronic airway infections are associated with a progressive decrease in lung function and overall increased patient morbidity and mortality. 1 Due to the recessive pattern of inheritance for CF, an affected individual must acquire one abnormal gene from each parent. Approximately 30,000 people in the United States are affected by CF, however, over 10 million Americans are carriers of the abnormal cystic fibrosis transmembrane conductance regulator (CFTR) gene. 2, 3 This condition affects all races, ethnicities and genders, but is most commonly found among Northern Europeans. 2 The precise cost of treating CF in recent years is unknown, however data from 1996 shows the direct cost per patient per year was up to $16,300 and lifetime direct costs were between $200,000 and $300, The exact number of healthcare visits per year for CF patients has not been explicitly calculated, however the recommendation is for quarterly evaluations, not including visits or hospitalizations for worsening symptoms or pulmonary exacerbations, medication changes, social work visits or dietary evaluations. 5 CF is caused by an inherited defect in the CFTR gene that encodes for an ion channel protein responsible for controlling salt and water movement within the cell. 2 There are a wide variety of known mutations that can affect the function of the CFTR gene, however all create a dysfunctional protein which results in thick, persistent mucus secretions. 2 Symptoms involve the
5 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 2 sinuses, lungs, skin, liver, pancreas, gastrointestinal tract and reproductive organs and include salty sweat, increased thick mucus production leading to chronic sinus and airway infections, dyspnea, pancreatitis, diabetes, malnutrition, and infertility. 2 Respiratory failure is the most common cause of death in CF patients, and it is due to an accumulation of tissue damage from chronic and/or recurrent pulmonary infections. 2 There is no known cure for CF at this time. 3 Treatment of CF is multifactorial and involves a variety of body systems and treatment methods. Patients are instructed in a variety of airway clearance techniques including postural drainage, percussion, inflatable vests, pulmonary rehabilitation with exercise training, and breathing strategies. 3,6 Inhaled medications such as mucolytics, antibiotics, bronchodilators and hypertonic saline, as well as oral or IV antibiotics in severe exacerbations, have been utilized for airway infections and worsening respiratory symptomatology. 3,6 Nutrition is another focus, with supplementation implemented involving a high caloric diet, feeding tube, pancreatic enzyme supplementation and specific nutrient supplementation when medically necessary. 3,6 Surgical procedures including nasal polyp removal, endoscopy with lavage, and lung transplantation are employed as a last resort to aid in respiratory function. 3,6 Currently, tobramycin is the most commonly used inhaled antibiotic for exacerbations of respiratory infections in CF patients, and has been shown to be effective against P. aeruginosa. 3,6 Since aztreonam is a monobactam antibiotic that has also been shown to have antipseudomonal properties, many studies have begun to explore inhaled aztreonam lysine as a potential effective intervention to relieve symptoms and treat P. aeruginosa airway infection. OBJECTIVE The objective of this selective EBM review is to determine whether or not aztreonam
6 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 3 lysine for inhalation is effective in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa airway infection. METHODS Three randomized, double-blind, placebo-controlled studies were included in this selective EBM review. The studies involved males and females 6 years of age and older with established CF and P. aeruginosa airway infection. Inclusion criteria consisted of studies that were randomized, controlled, double blind and published after 1996, with patients that were 6 years of age and older with current P. aeruginosa airway infections. Exclusion criteria comprised of patients under the age of 6 and those that utilized repeated courses of treatment with AZLI. The intervention was inhaled aztreonam lysine (AZLI) via nebulizer with a formulation of 75 mg of aztreonam and 52.5 mg of lysine monohydratae diluted in 1 ml of 0.17% NaCl. The comparison group received a visually matched placebo via nebulizer with a formulation of 5 mg lactose diluted in 1mL of 0.17% NaCl. Outcomes addressed included patient-reported impact on respiratory symptoms and symptom or health exacerbation requiring use of oral, IV or additional inhaled antipseudomonal antibiotics. Outcomes were measured by utilizing the CF Questionnaire-Revised where points ranged from and increasing scores indicated improvement of symptoms, as well as explicitly counting patients who required use of added antipseudomonal antibiotics during the treatment or follow up period specified by the individual study. Author searched articles within PubMed and The Cochrane Central Register of Controlled Trials (CENTRAL) databases between 2012 and Searches were conducted using keywords aztreonam, monobactam, cystic fibrosis, and Pseudomonas aeruginosa. Included articles were published in English, in 2008, 2009 and 2011, and selected based on their
7 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 4 relevance to CF patients with P. aeruginosa airway infections and because they addressed patient-oriented outcomes (POEMs). Each article was published in a peer-reviewed journal. Table 1 Demographics and Characteristics of Included Studies Study Type # Pts Age Inclusion Criteria Exclusion Criteria W/D Intervention McCoy Double (2008) 1 -blind RCT yrs old Retsch- Bogart (2009) 7 Wainwright (2011) 8 Double -blind RCT Double -blind RCT yrs old yrs old 6 yrs old, documented CF, current P. aeruginosa airway infection, 3+ tobramycin inhalation solution courses w/i last yr FEV 1 25% and 75% predicted, arterial oxygen saturation 90% on room air 6 yrs old, documented CF, P. aeruginosa airway infection, FEV1 25% to 75% predicted, arterial oxygen saturation 90% on room air 6 yrs, documented CF, P. aeruginosa airway infection, FEV 1 75% predicted; 2 chronic or intermittent CF symptoms for 28 days before baseline - Current oral corticosteroid use, daily O2 supplementation or intolerance to the study s medications - Recent changes in antimicrobial, bronchodilator, anti-inflammatory, corticosteroid medications or physiotherapy technique/schedule - Acute findings on chest radiograph w/i past 90 days, high AST, ALT, or SCr levels, or airway cultures of Burkholderia cepacia w/i past 2 yrs - Pregnant, lactating, lung transplant, or a medical or psychiatric illness interfering with study - Anti-pseudomonal antibiotic or azithromycin use w/i past 28 days - Current oral corticosteroid use, daily O2 supplementation >2 L/min at night or intolerance to the study s medications - Recent changes to antimicrobial, bronchodilator, anti-inflammatory or corticosteroid medications or physiotherapy technique/schedule - Acute findings on chest radiograph w/i 90 days, high AST, ALT, or SCr levels, or airway cultures of Burkholderia cepacia w/i past 2 yrs - Pregnant, lactating, lung transplant, or a medical or psychiatric illness that interferes with study - Pregnant, lactating, lung transplant, or a medical or psychiatric illness that interferes with study participation - Previous enrollment in AZLI trial, or acute findings on chest radiograph - Changes in antimicrobial, bronchodilator, or corticosteroid medications or physiotherapy technique/schedule w/i 7 days -Anti-pseudomonal antibiotic w/i past 28 days -Intolerance to the study s medications day course of tobramycin inhalation solution (TIS) followed by a 28 day course of 75 mg AZLI with nebulizer BID or TID day treatment course of 75 mg aztreonam lysine for inhalation administere d by nebulizer TID 4 28 day course of AZLI with nebulizer TID (doses separated 4 hrs)
8 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 5 The statistics utilized from the article or calculated by the author included relative benefit increase (RBI), absolute benefit increase (ABI), number needed to treat (NNT), relative risk increase (RRI), absolute risk increase (ARI), number needed to harm (NNH), 95% confidence intervals (CI) and p-values. OUTCOMES MEASURED There were a variety of outcomes addressed by each study, however the author utilized outcomes that served as POEM s to address the research question. McCoy et al (2008) included patients with significant lung disease (FEV 1 25% to 75% predicted) and who had been compliant with the standard CF treatment of maintenance tobramycin inhalation solution (TIS) treatment courses in their study. All study participants were administered a 28 day course of open-label TIS (300 mg twice daily) and then randomized into a 1:1:1 grouping of AZLI (75mg of aztreonam, 52.5 mg of lysine monohydrate diluted in 1 ml of 0.17% NaCl solution) either twice or three times daily, or placebo (5 mg lactose diluted in 1 ml of 0.17% NaCl solution) via nebulizer for a treatment period of 28 days. Patients were monitored on Day 14, Day 28, and Days 42, 56, 70 and 84 during the follow up period. The outcome addressed was change in patient reported respiratory symptoms, measured by utilizing the Cystic Fibrosis Questionnaire-Revised (CFQ-R). Minimal clinically important difference (MCID) score of 5 was used by to analyze results as it corresponds to the smallest change in symptoms noticeable by patients. Therefore, a 5 point change or more indicated improved or worsened symptoms. At Day 28 of treatment, patients were categorized as improved ( 5 point increase from baseline CFQ-R Respiratory scores), worsened ( 5 point decrease from baseline)
9 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 6 or stable/unchanged (< 5 point change). Comparisons between the experimental and the control groups were made throughout treatment and the designated follow up period. Retsch-Bogart et al (2009) focused on patients with moderate to severe lung disease (determined by a FEV 1 25% to 75% predicted) who had not been administered any inhaled, IV, or oral anti-pseudomonas antibiotics, azithromycin or aerosolized hypertonic saline solution within the past 28 days prior to the date of screening. Patients were split into groups via a 1:1 randomization, with the interventional group receiving 75 mg AZLI administered by nebulizer three times daily for 28 days and the control group receiving a visually matched placebo at the same interval for the same duration of time. The outcome addressed was change in patient reported respiratory symptoms, measured by the CFQ-R. Analysis of the questionnaire and MCID were the same as McCoy et al. Patients were followed throughout treatment and the 2 week follow up period. Comparisons between the experimental and control groups were made. Wainwright et al (2011) selected for patients with mild lung disease (FEV 1 75% predicted). Patients were randomly assigned (1:1) to treatment with 75 mg AZLI or placebo by nebulizer three times per day, doses separated by more than 4 hrs, for 28 days. Patients were monitored at Day 14, 28, and 42 for follow-up. The outcome was symptom(s) or health exacerbation requiring use of oral, IV, or additional inhaled antipseudomonal antibiotics during the study (28 day treatment period and 14 day follow up). The outcome was measured by explicitly counting the number of patients who required use of additional antipseudomonal antibiotics in the control and experimental groups. RESULTS The focus of this EBM review is patient oriented outcome measures, so only those will be presented in the following section. Two of the randomized control trials, McCoy et al and
10 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 7 Retsch-Bogart et al, utilized the CFQ-R to determine patient reported respiratory symptoms as a means to evaluate the treatments. The third study assessed pulmonary exacerbation that required additional antipseudomonal antibiotics to determine patient outcome. In McCoy et al, of the 246 patients enrolled and assigned groups by a 1:1:1 randomization, 211 completed the 28 day course of TIS and received at least 1 dose of AZLI or placebo, and therefore comprised the intention to treat population patients (82%) completed the 28 day treatment, and 90 (43%) completed the follow-up period. 1 Responses of twice versus three times per day dosing placebo groups were pooled for the efficacy analyses and were compared with the AZLI-pooled group. Analysis of CFQ-R used the last observation carried forward convention. At the conclusion of treatment (Day 28), adjusted mean CFQ-R respiratory scores increased 5.01 points in the AZLI-pooled group compared to placebo (95% CI, 0.81 to 9.21; P = 0.020), showing significance for AZLI in decreasing respiratory symptoms versus placebo. 1 During the treatment period, the AZLI-treated patients had more improved CFQ-R respiratory scores and less worsened respiratory scores compared with placebo-treated patients (overall categorical comparison, P = 0.029). 1 52% of AZLI treated patients and 37% of placebo had a greater than 5 point increase in respiratory score and 28% of AZLI versus 38% of placebo had a greater than 5 point decrease in respiratory score. 1 For improved CFQ-R scores, the RBI was calculated to be 40.54%, the ABI was 15% and the NNT was seven (Table 2). Therefore, for every 7 patients treated with AZLI, one more patient showed improved respiratory symptoms compared to the control. For worsened CFQ-R scores, the calculated RRI was %, the ARI was -10% and the NNH was -10 patients (Table 3). This means that for every 10 patients treated with AZLI, one less had worsened respiratory symptoms.
11 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 8 Table 2. Improved Respiratory Score on CRQ-R During Treatment Period (Day 0-28) 1 CER EER RBI ABI NNT 37% 52% 41% 15% 7 patients Table 3. Worsened Respiratory Score on CRQ-R During Treatment Period (Day 0-28) 1 CER EER RRI ARI NNH 38% 28% -26% -10% -10 patients The study of Retsch-Bogart, et al focused on patients without recent use of antipseudomonal antibiotics or azithromycin and had a primary efficacy endpoint of change in patient reported respiratory symptoms analyzed through the use of the CFQ-R scale. Patients were randomly assigned (1:1) a 28 day treatment of 75 mg AZLI or placebo at three times per day dosing and monitored throughout treatment and a 14 day follow up period. 7 Of the 164 patients who enrolled and began treatment, 138 completed the 28 day treatment period and 124 (76%) completed the study through the follow-up. 7 At day 28, patients were categorized as improved, worse, or stable based on their change from baseline CFQ-R respiratory scores. Five point or greater changes were determined to be the minimal clinically important difference and used to dichotomize the patient data into the categories by Retsch-Bogart, et al. 7 The adjusted mean CFQ-R respiratory scores showed a significant improvement in the AZLI group and decline in the placebo group at Day 28, the conclusion of the treatment period (9.7 point difference, 95% CI, 4.3 to 15.1; P < 0.001). 7 Also established at the conclusion of treatment, the data showed AZLI was shown to be significantly better in improving CFQ-R respiratory scores, and less likely to cause worsened respiratory scores, compared to the placebo group (P = for overall comparison). 7 In the AZLI group, 56% showed a greater than 5 point increase in respiratory score and 25% showed a greater than 5 point decrease in respiratory score, compared with the placebo group of 37% and 45%, respectively. 7 The calculated NNT was 6, meaning that for every 6 patients treated with AZLI, one more had improved respiratory
12 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 9 symptoms (Table 4). The calculated NNH was -5, meaning that for every 5 patients treated with AZLI, one less patient will have worsened respiratory symptoms (Table 5). Table 4. Improved Respiratory Score on CRQ-R at Treatment End (Day 28) 7 CER EER RBI ABI NNT 37% 56% 51% 19% 6 patients Table 5. Worsened Respiratory Score on CRQ-R at Treatment End (Day 28) 7 CER EER RRI ARI NNH 45% 25% -44% -20% -5 patients In Wainwright, et al, patients were treated with 28 days of 75 mg AZLI or placebo at three times per day dosing and followed for an additional 14 days. 8 The study enrolled and randomly assigned 160 patients, 156 (98%) of which completed the study. 8 Efficacy was assessed by comparing the number of patients that required additional oral, IV, or inhaled antibiotics during the treatment period and follow up. The need for additional antibiotics was similar amongst both the experimental and control groups from baseline through the follow up period (AZLI, 25%; placebo, 25.9%; p >0.999). 8 AZLI treatment did not significantly prevent symptoms or health exacerbations requiring additional antibiotics. The calculated NNH was This means that for every 112 patients treated with AZLI, one less will require additional antipseudomonal antibiotics than compared to the control (Table 6) Table 6. Need for Additional Antipseudomonal Antibiotics During Study 8 CER EER RRI ARI NNH 25.9% 25% 3.5% 0.9% -112 patients DISCUSSION To summarize the data within the three studies analyzed, it can be concluded that 75 mg of AZLI is effective at reducing respiratory symptoms in CF patients with chronic P. aeruginosa airway infection and moderate to severe respiratory dysfunction (FEV 1 between 25% and 75% predicted) compared to placebo. AZLI therapy did not significantly decrease the severe
13 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 10 pulmonary exacerbations that would require further antipseudomonal antibiotics in patients with mild respiratory dysfunction, or a FEV1 > 75% predicted. However, in the study that evaluated need for additional antibiotics, patients had a modest symptomatic baseline, and therefore any deviation from that may have prompted patients to seek additional treatment whether they truly needed it or not. There were several limitations and flaws in the three research studies. While this EBM review included a population of CF patients over the age of 6, all three of these studies had significantly more adults participate than children. The study performed by McCoy, et al specifically had 78% of their participants over the age of Retsch-Bogart, et al utilized a population where 77.4% were over the age of 18. As a general rule, along with standards of care at this point in time, more adults than children will have the moderate to severe lung impairment necessary to enter this specific study, and their disease progression may be more responsive to treatment. Therefore, these two studies may conclude a greater efficacy for children <18 years old than might be accurate. Also with Retsch-Bogart, et al, the participants were treated with TIS before AZLI or placebo. This makes it difficult to state clearly whether AZLI alone showed significant benefit to patients, or if it was the adjunctive treatment with TIS that provided significant symptom improvement. Two of the three studies in this EBM review shared a significant patient drop out rate. While there were a wide variety of reasons as to the cause, poor patient compliance is a large issue both in research and in the medical field. In the United States, as of 2005, of the long term treatments currently available, specifically TIS or macrolide therapy, 46% of eligible CF patients over the age of 6 were not receiving maintenance treatment. 7 In addition, patient compliance rates were less than ideal, ranging from 51% in older patients to 73% in younger individuals. 7
14 SHEVCHENKO, CYSTIC FIBROSIS AND AZTREONAM 11 Researchers and medical professionals need to work together with patients to develop additional treatment options for patients with chronic P. aeruginosa airway infection and emphasize the importance of treatment compliance for reducing morbidity and mortality. CONCLUSION According to the data generated from the three research studies compiled in this systemic review, AZLI has shown to be an effective treatment for patients with CF and chronic P. aeruginosa airway infection, whether pretreated with TIS and received proper maintenance therapy or not. Future research studies need to address whether inhaled antibiotic monotherapy is more efficacious in preventing pulmonary exacerbations and treating P. aeruginosa airway infections or if multiple products would provide greater benefit to patients. A longitudinal study to assess patient health both pre- and post-treatment periods with inhaled antibiotics, and to determine if multiple treatments would be more or less valuable to CF patients with chronic P. aeruginosa airway infection would be a useful undertaking. AZLI evaluated in the short term in these three studies has shown to be effective, but further investigation is necessary to determine if its use as a long-term suppressive therapy would be beneficial. Cystic fibrosis is a challenging condition to treat. Pulmonary involvement is debilitating for patients with regards to their ability to carry out daily activities. P. aeruginosa is notorious for being difficult to eradicate and responsible for increased mortality of those infected. 1 However, medical professionals have limited antibiotics that have shown to be both safe and effective in P. aeruginosa treatment. With continued research and patient compliance, CF patients will have improved quality of life and clinical outcomes.
15 REFERENCES 1. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9): doi: /rccm OC; /rccm OC. 2. Explore Cystic Fibrosis. National Heart, Lung, and Blood Institute Website. Accessed September 29, About Cystic Fibrosis. Cystic Fibrosis Foundation Website. Accessed September 29, Krauth C, Jalilvand N, Welte T, Busse R. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics. 2003;21(14): Cystic Fibrosis Outpatient Care Clinic. Nationwide Children s Website. Accessed September 29, Cystic Fibrosis. MayoClinic Website. Accessed September 29, Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5): doi: /chest ; /chest Wainwright CE, Quittner AL, Geller DE, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros. 2011;10(4): doi: /j.jcf ; /j.jcf
Cystic Fibrosis. Cystic fibrosis affects various systems in children and young adults, including the following:
Cystic Fibrosis What is cystic fibrosis? Cystic fibrosis (CF) is an inherited disease characterized by an abnormality in the glands that produce sweat and mucus. It is chronic, progressive, and is usually
More informationSummary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)
EMA/662624/2015 Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) This is a summary of the risk management plan (RMP) for Orkambi, which details the measures to be taken
More informationPulsating Aerosol. The New Wave in SINUSitis Therapy. Cystic Fibrosis. Focus on. For the precise, effective and gentle treatment of sinusitis
The New Wave in SINUSitis Therapy Focus on Cystic Fibrosis Pulsating Aerosol For the precise, effective and gentle treatment of sinusitis PARI SINUS Inhalation treatment for acute and chronic diseases
More informationCYSTIC FIBROSIS CLINICS AS A MODEL OF INTERPROFESSIONAL CARE
CYSTIC FIBROSIS CLINICS AS A MODEL OF INTERPROFESSIONAL CARE 1. Cystic fibrosis introduction 2. CF Foundation centers 3. Care disciplines: physician specialists (pulmonary, GI, endocrine, genetics, palliative
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 22 March 2007 Doc. Ref. EMEA/CHMP/EWP/81927/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT PAPER ON THE NEED FOR A GUIDELINE ON THE DEVELOPMENT OF
More informationIs Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept
More informationCF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core
CF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core Arlene Stecenko, MD Director, Emory + Children s Cystic Fibrosis Care Center
More informationThe Lung Clearance Index & Cystic Fibrosis. Dr. Reshma Amin Dr. Felix Ratjen s Lab PEM Research Rounds: October 14, 2008
The Lung Clearance Index & Cystic Fibrosis Dr. Reshma Amin Dr. Felix Ratjen s Lab PEM Research Rounds: October 14, 2008 Cystic Fibrosis (CF) Autosomal Recessive disease Cystic Fibrosis Transmembrane Conductance
More informationPulmonary Disorders. Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease (COPD)
RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Pulmonary Disorders Chronic Obstructive Pulmonary Disease (COPD) Characterized by decreased expiratory airflow Reduction in expiratory
More informationDepartment of Surgery
What is emphysema? 2004 Regents of the University of Michigan Emphysema is a chronic disease of the lungs characterized by thinning and overexpansion of the lung-like blisters (bullae) in the lung tissue.
More informationMedicare C/D Medical Coverage Policy
Nebulizer Medications Origination: June 17, 2009 Review Date: October 21, 2015 Next Review: October, 2017 Medicare C/D Medical Coverage Policy DESCRIPTION Nebulizer medications are used to prevent and
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationSYNOPSIS. Risperidone: Clinical Study Report CR003274
SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:
More informationJames F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationPatient Registry. Annual Data Report 2008
Patient Registry Annual Data Report 2008 Patients and families, The Cystic Fibrosis Foundation s mission is to develop the means to cure and control cystic fibrosis (CF) and to improve the quality of life
More informationPLAN OF ACTION FOR. Physician Name Signature License Date
PLAN OF ACTION FOR Patient s copy (patient s name) I Feel Well Lignes I feel short directrices of breath: I cough up sputum daily. No Yes, colour: I cough regularly. No Yes I Feel Worse I have changes
More informationCystic Fibrosis Webquest Sarah Follenweider, The English High School 2009 Summer Research Internship Program
Cystic Fibrosis Webquest Sarah Follenweider, The English High School 2009 Summer Research Internship Program Introduction: Cystic fibrosis (CF) is an inherited chronic disease that affects the lungs and
More informationPrevention of Acute COPD exacerbations
December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal
More informationCOPD and Asthma Differential Diagnosis
COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive
More informationGUIDELINE Sinusitis. David M. Poetker MD, MA Associate Professor. Division of Rhinology and Sinus Surgery
GUIDELINE Sinusitis David M. Poetker MD, MA Associate Professor Division of Rhinology and Sinus Surgery Guideline Fokkens et al. The European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology.
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationRiociguat Clinical Trial Program
Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension
More informationSponsor Novartis Pharmaceuticals
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study
More informationIdiopathic Pulmonary Fibrosis (IPF) Research
Idiopathic Pulmonary Fibrosis (IPF): Why Early Referral is Critical Even if Your Patient is Not Eligible for a Clinical Trial Idiopathic Pulmonary Fibrosis (IPF) Research Management of IPF requires a confident
More informationINHALED HYPERTONIC SALINE (7%) IMPROVES THE LUNG CLEARANCE INDEX IN CF PAEDIATRIC PATIENTS WITH FEV 1 % PREDICTED 80% By Reshma Amin
INHALED HYPERTONIC SALINE (7%) IMPROVES THE LUNG CLEARANCE INDEX IN CF PAEDIATRIC PATIENTS WITH FEV 1 % PREDICTED 80% By Reshma Amin A thesis submitted in conformity with the requirements for the degree
More informationThe patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.
Emergency Room Asthma Management Algorithm The Emergency Room Asthma Management Algorithm is to be used for any patient seen in the Emergency Room with the diagnosis of asthma. (The initial history should
More informationTechnology appraisal guidance Published: 27 March 2013 nice.org.uk/guidance/ta276. NICE 2013. All rights reserved.
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis Technology appraisal guidance Published: 27 March 2013 nice.org.uk/guidance/ta276
More informationGenetic Mutations. Indicator 4.8: Compare the consequences of mutations in body cells with those in gametes.
Genetic Mutations Indicator 4.8: Compare the consequences of mutations in body cells with those in gametes. Agenda Warm UP: What is a mutation? Body cell? Gamete? Notes on Mutations Karyotype Web Activity
More informationManagement of exacerbations in chronic obstructive pulmonary disease in Primary Care
Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.
More informationOral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication
More informationTests. Pulmonary Functions
Pulmonary Functions Tests Static lung functions volumes Dynamic lung functions volume and velocity Dynamic Tests Velocity dependent on Airway resistance Resistance of lung tissue to change in shape Dynamic
More informationPCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators]
PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators] Department of Neuroscience, Physiology and Pharmacology 215-871-6880 PATIENT
More informationJ of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575
EFFECT OF BREATHING EXERCISES ON BIOPHYSIOLOGICAL PARAMETERS AND QUALITY OF LIFE OF PATIENTS WITH COPD AT A TERTIARY CARE CENTRE Sudin Koshy 1, Rugma Pillai S 2 HOW TO CITE THIS ARTICLE: Sudin Koshy, Rugma
More informationHow transatlantic cooperation can speed-up efficient drug development: CF specific clinical trial networks Berlin, May 9 th, 2014
How transatlantic cooperation can speed-up efficient drug development: CF specific clinical trial networks Berlin, May 9 th, 2014 Kris De Boeck ECFS vice president Previous director of ECFS-CTN But median
More informationPulsating Aerosol. The New Wave in SINUSitis Therapy. For the precise, effective and gentle treatment of sinusitis
The New Wave in SINUSitis Therapy Pulsating Aerosol For the precise, effective and gentle treatment of sinusitis PARI SINUS Inhalation treatment for acute and chronic diseases of the upper airways www.parimedical.co.uk
More informationThe use of text messaging to improve asthma control: a pilot study using the mobile phone short messaging service (SMS)
RESEARCH Original article... Q The use of text messaging to improve asthma control: a pilot study using the mobile phone short messaging service (SMS) Lathy Prabhakaran*, Wai Yan Chee*, Kia Chong Chua,
More informationIs Acupuncture An Effective Treatment For Diabetic Peripheral Neuropathy?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Acupuncture An Effective Treatment
More informationCystic Fibrosis. - incidence: 1 in 2000-3000; predominantly Caucausian populations (carrier frequency 1 in 22-28)
Cystic Fibrosis - lethal autosomal recessive disease - incidence: 1 in 2000-3000; predominantly Caucausian populations (carrier frequency 1 in 22-28) - disease gene CFTR (cystic fibrosis transmembrane
More informationSummary of the risk management plan (RMP) for Ofev (nintedanib)
EMA/738120/2014 Summary of the risk management plan (RMP) for Ofev (nintedanib) This is a summary of the risk management plan (RMP) for Ofev, which details the measures to be taken in order to ensure that
More informationwritten by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org/copd
written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org/copd What Is COPD? COPD stands for chronic obstructive pulmonary disease. There are two major diseases included in
More informationChronic Medications for Maintenance of Lung Health
AJRCCM Articles in Press. Published on August 29, 2007 as doi:10.1164/rccm.200705-664oc Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health Patrick A. Flume, M.D. 1,
More informationStatistics of Type 2 Diabetes
Statistics of Type 2 Diabetes Of the 17 million Americans with diabetes, 90 percent to 95 percent have type 2 diabetes. Of these, half are unaware they have the disease. People with type 2 diabetes often
More informationThe Global Alliance against Chronic Respiratory Diseases
The Global Alliance against Chronic Respiratory Diseases Pulmonary hypertension Dr Marc Humbert What is the burden of pulmonary hypertension? The true burden of pulmonary hypertension is currently unknown
More informationCompare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma
Chapter 31 Drugs Used to Treat Lower Respiratory Disease Learning Objectives Describe the physiology of respirations Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis,
More informationSARCOIDOSIS. Signs and symptoms associated with specific organ involvement can include the following:
SARCOIDOSIS Sarcoidosis is a disease that occurs when areas of inflammation develop in different organs of the body. Very small clusters of inflammation, called granulomas, are seen with sarcoidosis. They
More informationVITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS
39 Chapter 3 VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS Maxine Briggs TABLE OF CONTENTS I. Review of the
More informationCOPD It Can Take Your Breath Away www.patientedu.org
written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org What Is COPD? COPD stands for chronic obstructive pulmonary disease. There are 2 major diseases included in COPD:
More informationEmphysema. Introduction Emphysema is a type of chronic obstructive pulmonary disease, or COPD. COPD affects about 64 million people worldwide.
Emphysema Introduction Emphysema is a type of chronic obstructive pulmonary disease, or COPD. COPD affects about 64 million people worldwide. Emphysema involves damage to the air sacs in the lungs. This
More informationPharmacology of the Respiratory Tract: COPD and Steroids
Pharmacology of the Respiratory Tract: COPD and Steroids Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationCystic fibrosis and bone health
Cystic fibrosis and bone health Factsheet March 2013 Cystic fibrosis and bone health Introduction As we get older our bones become thinner and weaker, and may become more susceptible to fracture. However
More informationCOPD - Education for Patients and Carers Integrated Care Pathway
Patient NHS COPD - Education for Patients and Carers Integrated Care Pathway Date ICP completed:. Is the patient following another Integrated Care Pathway[s].. / If yes, record which other Integrated Care
More informationMANAGING ANEMIA. When You Have Kidney Disease or Kidney Failure. www.kidney.org
MANAGING ANEMIA When You Have Kidney Disease or Kidney Failure www.kidney.org About the Information in this Booklet Did you know that the National Kidney Foundation (NKF) offers guidelines and commentaries
More informationFREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C
FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hunter syndrome is a rare genetic disease which mainly affects males of all ethnicities. The incidence rate ranges from 0.6 to
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationIs Topical 1% Pimecrolimus Cream an Effective Treatment for Rosacea?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Topical 1% Pimecrolimus Cream an Effective
More informationRecurrent or Persistent Pneumonia
Recurrent or Persistent Pneumonia Lower Respiratory Tract Dr T Avenant Recurrent or Persistent Pneumonia Definitions Recurrent pneumonia more than two episodes of pneumonia in 18 months Persistent pneumonia
More informationA Telehomecare monitoring project in Cystic Fibrosis
ICEHTM 2011 1st International Conference on E-HEALTH and TELEMEDICINE 10-12 October 2011 Nicosia - North Cyprus A Telehomecare monitoring project in Cystic Fibrosis Murgia F, Alghisi F, Majo F, Montemitro
More informationCritical Appraisal of Article on Therapy
Critical Appraisal of Article on Therapy What question did the study ask? Guide Are the results Valid 1. Was the assignment of patients to treatments randomized? And was the randomization list concealed?
More informationIf several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
More informationMedicare C/D Medical Coverage Policy
Medicare C/D Medical Coverage Policy Oxygen and Oxygen Supplements Origination: April 10, 1992 Review Date: July 15, 2015 Next Review: July, 2017 DESCRIPTION OF PROCEDURE OR SERVICE USP Oxygen is a gaseous
More informationOutcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
More information2. Background This drug had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Ambrisentan, tablets, 5 mg and 10 mg, Volibris Sponsor: GlaxoSmithKline Australia Pty Ltd Date of PBAC Consideration: July 2009 1. Purpose of Application The submission
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationSTATE OF NEBRASKA STATUTES RELATING TO RESPIRATORY CARE PRACTICE ACT
2012 STATE OF NEBRASKA STATUTES RELATING TO RESPIRATORY CARE PRACTICE ACT Department of Health and Human Services Division of Public Health Licensure Unit 301 Centennial Mall South, Third Floor PO Box
More informationProbiotics for the Treatment of Adult Gastrointestinal Disorders
Probiotics for the Treatment of Adult Gastrointestinal Disorders Darren M. Brenner, M.D. Division of Gastroenterology Northwestern University, Feinberg School of Medicine Chicago, Illinois What are Probiotics?
More informationSponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
More informationBronchodilators in COPD
TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for
More informationSelective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org
Selective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org About this booklet This booklet provides information on selective IgA deficiency (sigad). It has been produced by the PID UK
More informationELEMENTS FOR A PUBLIC SUMMARY. Overview of disease epidemiology. Summary of treatment benefits
VI: 2 ELEMENTS FOR A PUBLIC SUMMARY Bicalutamide (CASODEX 1 ) is a hormonal therapy anticancer agent, used for the treatment of prostate cancer. Hormones are chemical messengers that help to control the
More informationVersion History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
More informationBREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt
Ali A. Kader, S. (2010). Breast cancer awareness for women and men. UCQ Nursing Journal of Academic Writing, Winter 2010, 70 76. BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader Two years
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationLothian Guideline for Domiciliary Oxygen Therapy Service for COPD
Lothian Guideline for Domiciliary Oxygen Therapy Service for COPD This document describes the standard for clinical assessment, prescription, optimal management and follow-up of patients receiving domiciliary
More informationAsthma in Infancy, Childhood and Adolescence. Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California
Asthma in Infancy, Childhood and Adolescence Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California Major Health Problem in Childhood Afflicts 2.7 million children in the USA
More informationLife Insurance Application Form
Life Insurance Application Form INSTRUCTION To be completed by all applicants PERSONAL DETAILS Surname First name Middle name Sex Female Male Marital status (please tick) Single Married Other Current residential
More informationTeriflunomide (Aubagio) 14mg once daily tablet
Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationMetabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement
CLINICALLY T E S T E D Natural Blood Sugar Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Metabolic Syndrome with Prediabetic
More informationA Comparison of COPD Patients Quality of Life Using the Harmonica as a Means of Pulmonary Rehabilitation. Sharon Miller RN, BSN, CCRN
A Comparison of COPD Patients Quality of Life Using the Harmonica as a Means of Pulmonary Rehabilitation Sharon Miller RN, BSN, CCRN Background Very little research has been done on COPD patients playing
More informationSurgery in Individuals Age 65+ Possible Risks. Possible Benefits. Potential Causes of POCD 11/24/2014. What is POCD?
Surgery in Individuals Age 65+ Postoperative Cognitive Dysfunction in Older Adults Ryan W. Schroeder, Psy.D., LP, ABPP-CN Neuropsychologist & Assistant Professor University of Kansas School of Medicine
More informationA Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis
A Phase 2 Study of (Avonex ) in Ulcerative Colitis - Study Results - ClinicalTrials.gov A Phase 2 Study of (Avonex ) in Ulcerative Colitis This study has been completed. Sponsor: Biogen Idec Information
More informationCommunity health care services Alternatives to acute admission & Facilitated discharge options. Directory
Community health care services Alternatives to acute admission & Facilitated discharge options Directory Introduction The purpose of this directory is to provide primary and secondary health and social
More informationHawaii Administrative Rules. Title 11. Department of Health. Chapter 164. Tuberculosis
Hawaii Administrative Rules Title 11 Department of Health Chapter 164 Tuberculosis 11-164-1 Purpose 11-164-2 Definitions 11-164-3 Reports to the department 11-164-4 Content of report 11-164-5 Examination
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationSevere asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital
Severe asthma Definition, epidemiology and risk factors Mina Gaga Athens Chest Hospital Difficult asthma Defined as asthma, poorly controlled in terms of chronic symptoms, with episodic exacerbations,
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationGFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working
GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National
More informationLocal Clinical Trials
Local Clinical Trials The Alzheimer s Association, Connecticut Chapter does not officially endorse any specific research study. The following information regarding clinical trials is provided as a service
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationHEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE
HEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE The following diagnostic tests for Obstructive Sleep Apnea (OSA) should
More informationMarilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT
More informationPRIORITY RESEARCH TOPICS
PRIORITY RESEARCH TOPICS Understanding all the issues associated with antimicrobial resistance is probably impossible, but it is clear that there are a number of key issues about which we need more information.
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationPulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Development of disability in COPD The decline in airway function may initially go unnoticed as people adapt their lives to avoid
More information2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:
More information1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net
1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net Diabetes Mellitus (in cats) Diabetes, sugar Affected Animals: Most diabetic cats are older than 10 years of age when they are
More informationChronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) is the name for a group of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways
More informationThese factors increase your chance of developing emphysema. Tell your doctor if you have any of these risk factors:
Emphysema Pronounced: em-fiss-see-mah by Debra Wood, RN En Español (Spanish Version) Definition Emphysema is a chronic obstructive disease of the lungs. The lungs contain millions of tiny air sacs called
More information